Replication-defective adenovirus human type 5 recombinant as a vaccine carrier

Abstract

A replication defective recombinant adenovirus is provided which contains a complete deletion of its E1 gene and at least a partial deletion of its E3 gene, said virus containing in the site of the E1 deletion a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a heterologous protein from a disease-causing agent, which, when administered to a mammal in said recombinant virus, elicits a substantially complete protective immune response against the agent. Pharmaceutical and veterinary products containing the recombinant adenovirus are provided.

What is claimed is:  
     
         1 . A method of inducing an immune response in a mammal against a selected pathogen comprising: administering to a mammalian subject a sufficient amount of a recombinant adenovirus comprising a complete deletion of its E1 gene and at least a functional deletion of its E3 gene and, in the site of the E1 gene deletion, a sequence comprising a cytomegalovirus promoter directing the expression of DNA encoding a protein of said pathogen, which when administered to the subject in said recombinant virus, elicits an immune response against said pathogen.  
     
     
         2 . The method according to  claim 1 , wherein said adenovirus is administered subcutaneously, intranasally, intratracheally, or intramuscularly.  
     
     
         3 . A method of inducing an immune response in a mammal against human immunodeficiency virus HIV comprising: administering to a mammalian subject a sufficient amount of a recombinant adenovirus comprising a complete deletion of its E1 gene and at least a functional deletion of its E3 gene, and in the site of the E1 gene deletion, a sequence comprising a cytomegalovirus promoter directing the replication and expression of DNA encoding an HIV protein, which when administered to the subject in said recombinant virus, elicits an immune response against HIV.  
     
     
         4 . The method according to  claim 3 , wherein said adenovirus is administered subcutaneously, intranasally, intratracheally, or intramuscularly.  
     
     
         5 . A method of inducing an immune response in a mammal against human papilloma virus comprising: administering to a mammalian subject a sufficient amount of a recombinant adenovirus comprising a complete deletion of its E1 gene and at least a functional deletion of its E3 gene, and, in the site of the E1 gene deletion, a sequence comprising a cytomegalovirus promoter directing the replication and expression of DNA encoding a human papilloma virus protein, which when administered to the subject in said recombinant virus, elicits a protective immune response against human papilloma virus.  
     
     
         6 . The method according to  claim 5 , wherein said adenovirus is administered subcutaneously, intranasally, intratracheally, or intramuscularly.